IC50 values (nM) of mitoxantrone and imatinib determined by XTT assay in K562, and K562/BCRP-MX10 cells
. | K562 wild type . | . | K562/BCRP-MX10 . | . | ||
|---|---|---|---|---|---|---|
. | - FTC . | + FTC . | - FTC . | + FTC . | ||
| Mitoxantrone | 24.0 ± 4.6 (1.0) | 12.5 ± 3.7* | 283 ± 19.1 (11.8)†‡ | 21.3 ± 3.3* | ||
| Imatinib | 91.6 ± 10.8 (1.0) | 89.0 ± 30.3* | 274 ± 66.2 (3.0)§∥ | 94.5 ± 10.6* | ||
. | K562 wild type . | . | K562/BCRP-MX10 . | . | ||
|---|---|---|---|---|---|---|
. | - FTC . | + FTC . | - FTC . | + FTC . | ||
| Mitoxantrone | 24.0 ± 4.6 (1.0) | 12.5 ± 3.7* | 283 ± 19.1 (11.8)†‡ | 21.3 ± 3.3* | ||
| Imatinib | 91.6 ± 10.8 (1.0) | 89.0 ± 30.3* | 274 ± 66.2 (3.0)§∥ | 94.5 ± 10.6* | ||
Each value represents the mean value ± SEM (n = 8). Relative resistance is shown in parentheses as the ratio of the IC50 of K562-expressing BCRP over the IC50 of K562 wild type.
Two-sample t test versus K562 wild type without FTC; P = NS (not significant).
Two-sample t test versus K562 wild type without FTC; P < .001.
Two-sample t test versus K562/BCRP-MX10 with FTC; P < .001.
Two-sample t test versus K562 wild type without FTC; P < .05.
Two-sample t test versus K562/BCRP-MX10 with FTC; P < .05.